Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis

https://ift.tt/CGvUP8O

Dupixent^® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis

from Sanofi - Aventis Groupe https://ift.tt/u41spbn
via IFTTT

" May good health envelop you, spurring a quick recovery. .. "

from health care https://ift.tt/IhrJiwt
via IFTTT https://ift.tt/jJCuYr8